Jörg Hüser joined Axxam in June 2023 as Chief Scientific Officer, a role he held until December 31, 2024. Effective January 1, 2025, Jörg transitioned to being a member of Axxam’s Scientific Advisory Board, where he continues to leverage his extensive expertise and insights to support the company’s scientific direction and innovation.

Following his academic training in biology, Jörg’s career spans more than 20 years in various leadership positions within Bayer AG’s Pharma Research. Starting in Lead Discovery, he led bioassay and HTS activities at Bayer’s Wuppertal research campus from 2006 to 2015. Together with Medicinal Chemistry, his group established one of the industry’s leading small molecule discovery units, with a steadily growing multi-million compound library. By driving innovations in assay biology, plate reader technology, liquid handling, and lab automation, his team rigorously combined miniaturization in ultra-High-Throughput Screening with state-of-the-art cell-based and biochemical assay techniques to routinely screen the comprehensive collection, resulting in a number of products and numerous clinical pipeline assets.

In 2012, Jörg played a key role as part of a core team of EFPIA representatives to conceptualize and implement the IMI project European Lead Factory, a public-private partnership providing target ideas from academia access to industrial drug screening.

In 2015, he transitioned to oversee one of Bayer’s preclinical pharmacology groups focused on cardiovascular and pulmonary diseases. The scope of his responsibilities stretched from designing indication specific research strategies, driving the group’s project portfolio through preclinical development, to contributing to early clinical translation.